A Study of MK-2060 in Healthy Participants (MK-2060-016)

Completed · Phase 1 · Has a placebo group

Conditions studied: Venous Thrombosis

In brief

The goal of the study is to learn about the safety of MK-2060 and if people tolerate it when MK-2060 is given in different forms.

Key facts

Study ID

NCT06582602

Run by

Merck Sharp & Dohme LLC

People needed

23

Starts

2024-10-15

Expected to finish

2025-04-18

Last updated by the study team

2025-05-21

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The key inclusion criteria include but are not limited to the following:
• Is in good health before randomization
• Has a body mass index (BMI) between ≥18 and ≤32 kg/m\^2, inclusive

You may not qualify if…

• The key exclusion criteria include but are not limited to the following:
• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has a history of cancer

Where it is running

• Advanced Pharma CR, LLC ( Site 0002) — Miami, Florida, United States
• Alliance for Multispecialty Research, LLC ( Site 0001) — Knoxville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.